Table 1.
References | Sex/Age | Dose (mg/day) | Duration of Administration | Liver Pathology | Agranulocytosis | Comments | |
---|---|---|---|---|---|---|---|
1. | Spect & Boehme | F/67 | 30 | 30 days | central lobular congestion | + | death due to pneumonia |
2. | Rosenbaum & Reveno | F/62 | 10 | 7 weeks | – | + | – |
3. | Shipp | F/63 | 60 | 8 weeks | cholestasis | + | – |
4. | Tennenbaum & Dresken | F/38 | 60 | 4 weeks | cholestasis | − | skin rash |
5. | Lopez et al. | F/38 | 60 | 4 weeks | cholestasis | − | − |
6. | Becker et al. | F/54 | 40 | 24 days | focal hepatitis | − | death due to pneumonia |
7. | Fisher et al. | F/74 | 40 | 12 days | cholestasis | − | − |
8. | Vitug & Goldman | F/64 | 80 | 4 weeks | cholestasis | + | − |
9. | Schmidt et al. | F/58 | 20 | 20 days | cholestasis & fatty degeneration | + | − |
10. | Kravetz | ?/? | 30–50 | ? | cholestasis | − | − |
11. | Knopka et al. | F/37 | ? | ? | ? | ? | − |
12. | Manoijlovic | ?/? | 80–100 | ? | ? | + | − |
13. | Efstrtiadis | M/50 | 60 | ? | cholestasis | − | − |
14. | Sambe | F/30 | 40 | ? | – | − | − |
15. | Jansen & Froeling | F/62 | 40 | 5 weeks | cholestasis | − | − |
16. | Authors | M/43 | 30 | 17 weeks | cholestasis & focal hepatocellular injury | − | death due to hepatic failure |